Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1

Xianming Deng, Qingkai Yang, Nicholas Kwiatkowski, Taebo Sim, Ultan McDermott, Jeffrey E. Settleman, Jiing Dwan Lee, Nathanael S. Gray

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Kinome-wide selectivity profiling of a collection of 2-amino-pyrido[2,3-d] pyrimidines followed by cellular structure-activity relationship-guided optimization resulted in the identification of moderately potent and selective inhibitors of BMK1/ERK5 exemplified by 11, 18, and 21. For example, 11 possesses a dissociation constant (Kd) for BMK1 of 19 nM, a cellular IC 50 for inhibiting epidermal growth factor induced BMK1 autophosphorylation of 0.19 ± 0.04 μM, and an Ambit KINOMEscan selectivity score (S5) of 0.035. Inhibitors 18 and 21 are also potent BMK1 inhibitors and possess favorable pharmacokinetic properties which enable their use as pharmacological probes of BMK1-dependent phenomena as well as starting points for further optimization efforts.

Original languageEnglish
Pages (from-to)195-200
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume2
Issue number3
DOIs
Publication statusPublished - 2011 Mar 10
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase 7
Cellular Structures
Structure-Activity Relationship
Epidermal Growth Factor
Pharmacokinetics
Pharmacology
pyrido(3,2-d)pyrimidine

Keywords

  • BMK1
  • ERK5
  • MAPK

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Deng, X., Yang, Q., Kwiatkowski, N., Sim, T., McDermott, U., Settleman, J. E., ... Gray, N. S. (2011). Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Medicinal Chemistry Letters, 2(3), 195-200. https://doi.org/10.1021/ml100304b

Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. / Deng, Xianming; Yang, Qingkai; Kwiatkowski, Nicholas; Sim, Taebo; McDermott, Ultan; Settleman, Jeffrey E.; Lee, Jiing Dwan; Gray, Nathanael S.

In: ACS Medicinal Chemistry Letters, Vol. 2, No. 3, 10.03.2011, p. 195-200.

Research output: Contribution to journalArticle

Deng, X, Yang, Q, Kwiatkowski, N, Sim, T, McDermott, U, Settleman, JE, Lee, JD & Gray, NS 2011, 'Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1', ACS Medicinal Chemistry Letters, vol. 2, no. 3, pp. 195-200. https://doi.org/10.1021/ml100304b
Deng, Xianming ; Yang, Qingkai ; Kwiatkowski, Nicholas ; Sim, Taebo ; McDermott, Ultan ; Settleman, Jeffrey E. ; Lee, Jiing Dwan ; Gray, Nathanael S. / Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. In: ACS Medicinal Chemistry Letters. 2011 ; Vol. 2, No. 3. pp. 195-200.
@article{09a3edd5ea8a435aa095958916996b81,
title = "Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1",
abstract = "Kinome-wide selectivity profiling of a collection of 2-amino-pyrido[2,3-d] pyrimidines followed by cellular structure-activity relationship-guided optimization resulted in the identification of moderately potent and selective inhibitors of BMK1/ERK5 exemplified by 11, 18, and 21. For example, 11 possesses a dissociation constant (Kd) for BMK1 of 19 nM, a cellular IC 50 for inhibiting epidermal growth factor induced BMK1 autophosphorylation of 0.19 ± 0.04 μM, and an Ambit KINOMEscan selectivity score (S5) of 0.035. Inhibitors 18 and 21 are also potent BMK1 inhibitors and possess favorable pharmacokinetic properties which enable their use as pharmacological probes of BMK1-dependent phenomena as well as starting points for further optimization efforts.",
keywords = "BMK1, ERK5, MAPK",
author = "Xianming Deng and Qingkai Yang and Nicholas Kwiatkowski and Taebo Sim and Ultan McDermott and Settleman, {Jeffrey E.} and Lee, {Jiing Dwan} and Gray, {Nathanael S.}",
year = "2011",
month = "3",
day = "10",
doi = "10.1021/ml100304b",
language = "English",
volume = "2",
pages = "195--200",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1

AU - Deng, Xianming

AU - Yang, Qingkai

AU - Kwiatkowski, Nicholas

AU - Sim, Taebo

AU - McDermott, Ultan

AU - Settleman, Jeffrey E.

AU - Lee, Jiing Dwan

AU - Gray, Nathanael S.

PY - 2011/3/10

Y1 - 2011/3/10

N2 - Kinome-wide selectivity profiling of a collection of 2-amino-pyrido[2,3-d] pyrimidines followed by cellular structure-activity relationship-guided optimization resulted in the identification of moderately potent and selective inhibitors of BMK1/ERK5 exemplified by 11, 18, and 21. For example, 11 possesses a dissociation constant (Kd) for BMK1 of 19 nM, a cellular IC 50 for inhibiting epidermal growth factor induced BMK1 autophosphorylation of 0.19 ± 0.04 μM, and an Ambit KINOMEscan selectivity score (S5) of 0.035. Inhibitors 18 and 21 are also potent BMK1 inhibitors and possess favorable pharmacokinetic properties which enable their use as pharmacological probes of BMK1-dependent phenomena as well as starting points for further optimization efforts.

AB - Kinome-wide selectivity profiling of a collection of 2-amino-pyrido[2,3-d] pyrimidines followed by cellular structure-activity relationship-guided optimization resulted in the identification of moderately potent and selective inhibitors of BMK1/ERK5 exemplified by 11, 18, and 21. For example, 11 possesses a dissociation constant (Kd) for BMK1 of 19 nM, a cellular IC 50 for inhibiting epidermal growth factor induced BMK1 autophosphorylation of 0.19 ± 0.04 μM, and an Ambit KINOMEscan selectivity score (S5) of 0.035. Inhibitors 18 and 21 are also potent BMK1 inhibitors and possess favorable pharmacokinetic properties which enable their use as pharmacological probes of BMK1-dependent phenomena as well as starting points for further optimization efforts.

KW - BMK1

KW - ERK5

KW - MAPK

UR - http://www.scopus.com/inward/record.url?scp=79952661147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952661147&partnerID=8YFLogxK

U2 - 10.1021/ml100304b

DO - 10.1021/ml100304b

M3 - Article

AN - SCOPUS:79952661147

VL - 2

SP - 195

EP - 200

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 3

ER -